Pierre Paradis
  • Associate Director, Lady Davis Institute of Medical Research , Jewish General Hospital, McGill University, Canada
Research fields
  • Immunology, Molecular Biology
Personal information


PhD, Université de Montréal, 1993

Lab information

Ernesto Schiffrin lab

Research focus

Blood pressure, hypertension, cardiovascular disease, blood vessels, small artery remodeling, inflammation, immunity, renin-angiotensin-aldosterone, endothelin, endothelium


Peer Reviewed papers
91. Shokoples B,G., Comeau K., Higaki A., Ferreira N.S., Caillon A., Berillo O., Oukka M., Paradis P., Schiffrin E.L. Angiotensin II-induced a steeper blood pressure elevation in IL-23 receptor-deficient mice: Role of interferon-γ producing T cells. September 18, 2022. Hypertens Res. 2022 Oct 15. doi: 10.1038/s41440-022-01055-3. Online ahead of print.
90. Yang H., Wang Y., Tang M.C., Waters P., Wang S., Allard P., Ryan R.O., Nuyt A.M., Paradis P., Schiffrin E.L., Furtos A., Mitchell G.A. Cardiac-specific deficiency of 3-hydroxy-3-methylglutaryl coenzyme A lyase in mice causes cardiomyopathy and a distinct pattern of acyl-coenzyme A-related metabolites. Mol Genet Metab. 2022;137(3):257-264. doi: 10.1016/j.ymgme.2022.09.008. PMID: 36228350.
89. Berillo O., Huo K.G., Richer C., Fraulob-Aquino J.C., Briet M., Lipman M.L., Sinnett D., Paradis P., Schiffrin E.L. Distinct transcriptomic profile of small arteries of hypertensive patients with chronic kidney disease identified miR-338-3p targeting GPX3 and PTPRS. J Hypertens. 2022;40:1394-1405. doi: 10.1097/HJH.0000000000003160. Online ahead of print.
88. Demers J., Ton A.T., Huynh F., Thibault S., Ducharme A., Paradis P., Nemer M., Fiset C. Atrial Electrical Remodeling in Mice with Cardiac-Specific Overexpression of Angiotensin II Type 1 Receptor. J Am Heart Assoc. 2022 Apr 18;e023974. doi: 10.1161/JAHA.121.023974.
87. Rizzoni D., De Ciuceis C., Szczepaniak P., Paradis P., Schiffrin E.L., Guzik T.J. Immune system and microvascular remodeling in humans. Hypertension 2022;79:691-705. HYPERTENSIONAHA12117955. doi: 10.1161/HYPERTENSIONAHA.121.17955. PMID: 35098718
86. Higaki A., Mahmoud A.U.M., Paradis P, Schiffrin E.L. Automated detection and diameter estimation for mouse mesenteric artery using semantic segmentation. J. Vasc. Res. 2021;58:379-387. doi: 10.1159/000516842. PMID: 34182554
85. Berillo O., Coelho S.C., Mahjoub N., Offermanns S., Paradis P., Schiffrin E.L. Aldosterone contributes to hypertension in male mice inducibly overexpressing human endothelin-1 in endothelium. J Hypertens. 2021 Sep 1;39(9):1908-1917. doi: 10.1097/HJH.0000000000002880.PMID: 34039912.
84. Caillon A., Zhao K., Klein K.O., Greenwood C., Lu Z., Paradis P, Schiffrin E.L. High systolic blood pressure at hospital admission is an important risk factor in models predicting outcome of COVID-19 patients. Am J Hypertens. 2021;34, 282-290. doi: 10.1093/ajh/hpaa225. PMID: 33386395
83. Berillo O., Ouerd S., Idris-Khodja N., Rehman A., Richer C., Sinnett D., Kwitek A.E., Paradis P., Schiffrin E.L. Chromosome 2 Fragment Substitutions in Dahl Salt-Sensitive Rats and RNA Sequencing Identified Enpep and Hs2st1 as Vascular Inflammatory Modulators. Hypertension. 2021;77:178-189. doi: 10.1161/HYPERTENSIONAHA.120.15690. PMID: 33161775.
82. Shokoples BG, Paradis P, Schiffrin EL. P2X7: An Untapped Target for the Management of Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2021; 41, 186-199. doi: 10.1161/ATVBAHA.120.315116. PMID: 32998520
81. Comeau K., Paradis P., Schiffrin E.L. Human and Murine Memory γδ T Cells: Evidence for Acquired Immune Memory in Bacterial and Viral Infections and Autoimmunity. Cell Immunol. 2020 Sep 16;357:104217. doi: 10.1016/j.cellimm.2020.104217. PMID: 32979762
80. Higaki A., Mahmoud A.U.M., Paradis P., Schiffrin E.L. Role of Interleukin-23/Interleukin-17 Axis in T-Cell Mediated Actions in Hypertension. Cardiovasc Res. 2021; 117, 1274-1283. doi: 10.1093/cvr/cvaa257. PMID: 32870976
79. Ferreira N.D.S., Tostes R.C., Paradis P., Schiffrin E.L. Aldosterone, Inflammation, Immune System and Hypertension. Am J Hypertens. 2021; 34, 15-27. doi: 10.1093/ajh/hpaa137. PMID: 32820797
78. Ouerd S., Idris-Khodja N., Trindade M., Ferreira N.D.S., Berillo O., Coelho S.C., Neves M.F., Jandeleit-Dahm K.A., Paradis P., Schiffrin E.L. Endothelium-Restricted Endothelin-1 Overexpression in Type-1 Diabetes Worsens Atherosclerosis and Immune Cell Infiltration Via Nox1. Cardiovasc Res 2021; 117, 1144-1153. doi: 10.1093/cvr/cvaa168. PMID: 32533834.
77. Berillo O., Huo K.G., Fraulob-Aquino J.C., Richer C., Briet M., Boutouyrie P., Lipman M.L., Sinnett D., Paradis P., Schiffrin E.L. Circulating let-7g-5p and miR-191-5p are independent predictors of chronic kidney disease in hypertensive patients. Am J Hypertens. 2020 May;21;33(6):505-513. doi: 10.1093/ajh/hpaa031. PubMed PMID: 32115655.
76. Grunewald Z.I., Jurrissen T.J., Woodford M.L., Ramirez-Perez F.I., Park L.K., Pettit-Mee R., Ghiarone T., Brown S.C., Morales-Quinones M., Ball J.R., Staveley-O’Carroll K.F., Aroor A.R., Fadel P.J., Paradis P., Schiffrin E.L., Bender S.B., Martinez-Lemus L.A., Padilla J. Chronic Elevation of Endothelin-1 Alone May Not Be Sufficient to Impair Endothelium-Dependent Relaxation. Hypertension. 2019 Dec;74(6):1409-1419. doi: 10.1161/HYPERTENSIONAHA.119.13676. Epub 2019 Oct 21. PubMed PMID: 31630572; PubMed Central PMCID: PMC6854321.
75. Jurrissen T.J., Grunewald Z.I., Woodford M.L., Winn N.C., Ball J.R., Smith T.N., Wheeler A., Rawlings A.L., Staveley-O’Carroll K.F., Ji Y., Fay W.P., Paradis P., Schiffrin E.L., Vieira-Potter V.J., Fadel P.J., Martinez-Lemus L.A., Padilla J. Overproduction of endothelin-1 impairs glucose tolerance but does not promote visceral adipose tissue inflammation or limit metabolic adaptations to exercise. 2019. Am J Physiol Endocrinol Metab. 2019 Sep 1;317(3):E548-E558. doi: 10.1152/ajpendo.00178.2019. Epub 2019 Jul 16. PubMed PMID: 31310581; PubMed Central PMCID: PMC6766607.
74. Huo K.G., Richer C., Berillo O., Mahjoub N., Fraulob-Aquino J.C., Barhoumi T., Ouerd S., Coelho S.C., Sinnett D., Paradis P., Schiffrin E.L. miR-431-5p knockdown protects against angiotensin II-induced hypertension and vascular injury. Hypertension.2019 May;73(5):1007-1017. doi: 10.1161/HYPERTENSIONAHA.119.12619. PubMed PMID: 30929512.
73. Higaki A., Caillon A., Paradis P., Schiffrin E.L. Innate and Innate-Like Immune System in Hypertension and Vascular Injury. Curr Hypertens Rep. 2019;21:4. doi: 10.1007/s11906-019-0907-1. PMID: 30659373.
72. Iulita M.F., Duchemin S., Vallerand D., Barhoumi T., Alvarez F.; Istomine R.; Laurent C., Youwakim J., Paradis P., Arbour N, Piccirillo C.A., Schiffrin E.L., Girouard H.. CD4+ Regulatory T lymphocytes prevent impaired cerebral blood flow in angiotensin II-induced hypertension. Journal of the American Heart Association. 2019;8(1):e009372. PMID: 30572753. DOI: 10.1161/JAHA.118.009372
71. Caillon A., Paradis P., Schiffrin E.L. Role of Immune Cells in Hypertension. Br. J. Pharmacol. 2019;176:1818-1828. doi: 10.1111/bph.14427. DOI: 10.1111/bph.14427. PMID: 29952002.
70. Paradis P., Schiffrin E.L. CXCL1-CXCR2 lead monocytes to the heart of the matter. Eur Heart J. 2018;39:1832-1834. doi: 10.1093/eurheartj/ehy114. PubMed PMID: 29528395.
69. Mathieu S., El. Khoury N., Rivard K., Paradis P., Nemer M., Fiset C. Angiotensin II Overstimulation Leads to an Increased Susceptibility to Dilated Cardiomyopathy and Higher Mortality in Female Mice. Sci. Rep. 2018;8: 952, doi: 10.1038/s41598-018-19436-5. PubMed PMID: 29343862.
68. Coelho S.C., Berillo O., Caillon A., Ouerd S., Fraulob-Aquino J.C., Barhoumi T., Offermanns S., Paradis P. Schiffrin E.L. Three-Month Endothelial Human Endothelin-1 Overexpression Causes Blood Pressure Elevation and Vascular and Kidney Injury. Hypertension. 2018;71: 208-216. doi: 10.1161/HYPERTENSIONAHA.117.09925. Epub 2017 Nov 13. PubMed PMID: 29133362.
67. Caillon A., Huo K.G., Paradis P., Schiffrin E.L. Response by Caillon et al to Letter Regarding Article, "γδ T Cells Mediate Angiotensin II-Induced Hypertension and Vascular Injury". Circulation. 2017;36:2200-2201. doi: 10.1161/CIRCULATIONAHA.117.030517. PubMed PMID: 29180499.
66. Barhoumi T., Fraulob-Aquino J.C., Mian M.O.R., Idris-Khodja N., Huo K.G., Rehman A., Ouerd S., Caillon A., Dancose-Giambattisto B., Ebrahimian T., Lehoux S., Paradis P. Schiffrin E.L. Matrix Metalloproteinase-2 Knockout Prevents Angiotensin II-Induced vascular injury. Cardiovasc. Res. 2017; 113: 1753–1762. doi: 10.1093/cvr/cvx115.
65. Caillon A., Mian M.O.R., Fraulob-Aquino J.C., Huo K.G., Barhoumi T., Ouerd S., Sinnaeve P.R., Paradis P., Schiffrin E.L. γδ T Cells Mediate Angiotensin II-Induced Hypertension and Vascular Injury. Circulation. 2017 May 30;135:2155-2162. doi: 10.1161/CIRCULATIONAHA.116.027058. Epub 2017 Mar 22. PMID: 28330983
64. Idris-Khodja N., Ouerd S., Trindade M., Gornitsky J., Rehman A., Barhoumi T., Offermanns S., Gonzalez F.J., Neves M.F., Paradis P., Schiffrin E.L. Vascular smooth muscle cell peroxisome proliferator-activated receptor gamma protects against endothelin-1-induced oxidative stress and inflammation. J Hypertens. 2017; Jul;35:1390-1401. doi: 10.1097/HJH.0000000000001324. [Epub ahead of print]. PMID: 28234672
63. Idris-Khodja N., Ouerd S., Mian M.O., Gornitsky J., Barhoumi T., Paradis P., Schiffrin E.L. Endothelin-1 overexpression exaggerates diabetes-induced endothelial dysfunction by altering oxidative stress. Am J Hypertens. 2016 Jul 26. pii: hpw078. [Epub ahead of print]. PMID: 27465439
62. Briet M., Barhoumi T., Mian M.O.R., Coelho S.C., Ouerd S., Rautureau Y., Coffman T.M., Paradis P., Schiffrin E.L. Aldosterone-induced vascular remodeling and endothelial dysfunction require functional angiotensin type 1a receptors. Hypertension. 2016;67:897-905. doi: 10.1161/HYPERTENSIONAHA.115.07074. Epub 2016 Apr 4.
61. Mathieu S., El Khoury N., Rivard K., Gélinas R., Goyette P., Paradis P., Nemer M., Fiset C. Reduction in Na(+) current by angiotensin II is mediated by PKCα in mouse and human-induced pluripotent stem cell-derived cardiomyocytes. Heart Rhythm. 2016 Feb 24. pii: S1547-5271(16)00185-5. doi: 10.1016/j.hrthm.2016.02.015. [Epub ahead of print] PubMed PMID: 26921763.
60. Bertagnolli M., Dios A., Béland-Bonenfant S., Gascon G., Sutherland M., Lukaszewski M.A., Anik Cloutier A., Paradis P., Schiffrin E.L., Nuyt A.M. Activation of the cardiac renin-angiotensin system in high oxygen-exposed newborn rats: angiotensin receptor blockade prevents the developmental programming of cardiac dysfunction. Hypertension. 2016 Feb 8. pii: HYPERTENSIONAHA.115.06745. [Epub ahead of print] PubMed PMID: 26857347.
59. Mian M.O.R., Barhoumi T., Briet M., Paradis P., Schiffrin E.L. Deficiency of T-regulatory cells exaggerates angiotensin II-induced microvascular injury by enhancing immune responses. J Hypertens. 2016;34:97-108. DOI: 10.1097/HJH.0000000000000761.
58. Rautureau Y., Coelho S.C., Fraulob-Aquino J.C., Huo K.G., Rehman A., Offermanns S., Paradis P., Schiffrin E.L. Inducible human endothelin-1 overexpression in endothelium raises blood pressure via endothelin type A receptors. Hypertension. 2015;66:347-535. DOI:10.1161/HYPERTENSIONAHA.115.05168. Epub 2015 Jun 22.
57. Idris-Khodja N., Mian M.O.R., Paradis P., Schiffrin E.L. Dual opposing roles of adaptive immunity in hypertension. Eur Heart J. 2014;35:1238-44.
56. Barhoumi T., Briet M., Kasal D.A., Fraulob-Aquino J.C., Idris-Khodja N., Laurant P., Paradis P., Schiffrin E.L. Erythropoietin-induced hypertension and vascular injury in mice overexpressing human endothelin-1: exercise attenuated hypertension, oxidative stress, inflammation and immune response. J Hypertens. 2014;32:784-94.
55. Mian M.O.R., Paradis P., Schiffrin E.L. Innate immunity in hypertension. Curr Hypertens Rep. 2014;16:413.
54. Bertagnolli M., Huyard F., Cloutier A., Anstey Z., Huot-Marchand J.É., Fallaha C., Paradis P., Schiffrin E.L., Deblois D., Nuyt A.M. Transient neonatal high oxygen exposure leads to early adult cardiac dysfunction, remodeling, and activation of the Renin-Angiotensin system. Hypertension. 2014;63:143-50.
53. Mian M.O., Idris-Khodja N., Li M.W., Leibowitz A., Paradis P., Rautureau Y., Schiffrin E.L. Preservation of endothelium-dependent relaxation in atherosclerotic mice with endothelium-restricted endothelin-1 overexpression. J Pharmacol Exp Ther. 2013;347:30-7.
52. Li M.W., Mian M.O., Barhoumi T., Rehman A., Mann K., Paradis P., Schiffrin E.L. Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2013;33:2306-15.
51. Javeshghani D., Barhoumi T., Idris-Khodja N., Paradis P., Schiffrin E.L. Reduced macrophage-dependent inflammation improves endothelin-1-induced vascular injury. Hypertension. 2013;62:112-7.
50. Briet M., Barhoumi T., Mian M.O.R., Sierra C., Boutouyrie .P, Davidman M., Bercovitch D., Nessim S.J., Frisch G., Paradis P., Lipman M.L., Schiffrin E.L. Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease. J Am Heart Assoc. 2013;2:e000128.
49. Leibowitz A., Rehman A., Paradis P., Schiffrin E.L. Role of T Regulatory Lymphocytes in the Pathogenesis of High-Fructose Diet–Induced Metabolic Syndrome. Hypertension. 2013 Jun;61(6):1316-21. doi: 10.1161/HYPERTENSIONAHA.111.203521. Epub 2013 Mar 25.
48. Marchesi C., Rehman A., Rautureau Y., Kasal D.A., Briet M., Leibowitz A., Simeone S.M., Ebrahimian T., Neves M.F., Offermanns S., Gonzalez F.J., Paradis P., Schiffrin E.L. Protective role of vascular smooth muscle cell PPARγ in angiotensin II-induced vascular disease. Cardiovasc Res. 2013; 97(3):562-70.
47. Yamak A., Temsah R., Maharsy W., Caron S., Paradis P., Aries A., Nemer M. Cyclin D2 rescues size and function of GATA4 haplo-insufficient hearts. Am J Physiol Heart Circ Physiol. 2012; 303:H1057-66.
46 Yasuda N., Akazawa H., Ito K., Shimizu I., Kudo-Sakamoto Y., Yabumoto C., Yano M., Yamamoto R., Ozasa Y., Minamino T., Naito A.T., Oka T., Shiojima I., Tamura K., Umemura S., Paradis P., Nemer M. and Komuro I. Agonist-Independent Constitutive Activity of Angiotensin II Receptor Promotes Cardiac Remodeling in Mice. Hypertension. 2012;59: 627–633. Erratum in: in Hypertension. 2012, 59:e51.
45. Rehman A., Leibowitz A., Yamamoto N., Rautureau Y., Paradis P., Schiffrin E.L. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension. 2012;59:291-9.
44. Kasal D.A., Barhoumi T., Li M.W., Yamamoto N., Zdanovich E., Rehman A., Neves M.F., Laurant P., Paradis P., Schiffrin E.L. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension. 2012;59:324-30.
43. Bouchentouf M., Williams P., Forner K.A., Cuerquis J., Michaud V., Paradis P., Schiffrin E.L., Galipeau J. Interleukin-2 enhances angiogenesis and preserves cardiac function following myocardial infarction. Cytokine. 2011;56:732-8.
42. Rivard K., Grandy S.A., Douillette A., Paradis P., Nemer M., Allen B.G., Fiset C. Overexpression of type 1 angiotensin II receptors impairs excitation-contraction coupling in the mouse heart. Am J Physiol Heart Circ Physiol. 2011;301:H2018-27.
41. Marchesi C., Essalmani R., Lemarié C.A., Leibovitz E., Ebrahimian T., Paradis P., Seidah N.G., Schiffrin E.L., Prat A. Inactivation of endothelial proprotein convertase 5/6 decreases collagen deposition in the cardiovascular system: role of fibroblast autophagy. J Mol Med (Berl). 2011;89:1103-11.
40. Rautureau Y., Paradis P., Schiffrin E.L. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids. 2011; 76:834-839.
39. Bouchentouf M., Forner K., Cuerquis J., Boulassel M.R., Routy J.P., Waller E.K., Quyyumi A.A., Paradis P., Schiffrin E.L., Galipeau J. A novel and simplified method of culture of human blood derived early endothelial progenitor cells for the treatment of ischemic vascular disease. Cell Transplant. 2011; 20:1431-1443.
38. Barhoumi T., Kasal D.A., Li M.W., Shbat L., Laurant P., Neves M.F., Paradis P, Schiffrin E.L. T Regulatory Lymphocytes Prevent Angiotensin II–Induced Hypertension and Vascular Injury. Hypertension. 2011;57:469-476.
37. Ebrahimian T., Li M.W., Lemarié C.A., Simeone S.M., Pagano P.J., Gaestel M., Paradis P., Wassmann S., Schiffrin E.L. Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Angiotensin II-Induced Inflammation and Hypertension: Regulation of Oxidative Stress. Hypertension. 2011;57:245-254.
36. Lemarie C.A., Shbat L., Marchesi C., Angulo O.J., Deschênes M.E., Blostein M.D., Paradis P., Schiffrin E.L. Mthfr deficiency induces endothelial progenitor cell senescence via uncoupling of eNOS and downregulation of SIRT1. Am. J. Physiol. Heart Circ. Physiol. 2011; 300:H745-53.
35. Simeone S.M., Li M.W., Paradis P., Schiffrin E.L. Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. Physiol. Genomics. 2011;43:148-60.
34. Nadeau M., Georges R.O., Laforest B., Yamak A., Lefebvre C., Beauregard J., Paradis P., Bruneau B.G., Andelfinger G., Nemer M. An endocardial pathway involving Tbx5, Gata4, and Nos3 required for atrial septum formation. Proc. Natl. Acad. Sci. U. S. A. 2010;107:19356-19361.
33. Bouchentouf M., Forner K.A., Cuerquis J., Michaud V., Zheng J., Paradis P., Schiffrin E.L., Galipeau J. Induction of cardiac angiogenesis requires killer cell lectin-like receptor 1 and α4β7 integrin expression by NK cells. J. Immunol. 2010;185:7014-7025.
32. Viel E.C., Lemarié C.A., Benkirane K., Paradis P., Schiffrin E.L. Immune regulation and vascular inflammation in genetic hypertension. Am. J. Physiol. Heart Circ. Physiol. 2010;298:H938- H944.
31. Bouchentouf M., Paradis P., Forner K.A., Cuerquis J., Boivin M.N., Zheng J., Boulassel M.R., Routy J.P., Schiffrin E.L., Galipeau J. Monocyte derivatives promote angiogenesis and myocyte survival in a model of myocardial infarction. Cell Transplant. 2010;19:369-386.
30. Savoia C., Ebrahimian T., Lemarié C.A., Paradis P., Iglars M., Amiri F., Javeshghani D., Schiffrin E.L. Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: role of oxidative stress and PRMT-1. Clin. Sci. (Lond.). 2010;118:583-592.
29. Marchesi C., Ebrahimian T., Angulo O., Paradis P., Schiffrin E.L. Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. Hypertension. 2009;54:1384-1392.
28. Lemarié C.A., Simeone S.M., Nikonova A., Ebrahimian T., Deschênes M.E., Coffman T.M., Paradis P., Schiffrin E.L. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ. Res. 2009;105:852-859.
27. Leibovitz E., Ebrahimian T., Paradis P., Schiffrin E.L. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J. Hypertens. 2009;27:2192-2200.
26. Schiffrin E.L., Paradis P. Suppression of peroxisome proliferator-activated receptor-gamma activity by angiotensin II in vascular smooth muscle involves Bcr kinase: the fire that drowns the water. Circ. Res. 2009;104:4-6.
25. Marchesi C., Paradis P., Schiffrin E.L. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol. Sci. 2008;29:367-74.
24. Lemarié C.A., Paradis P., Schiffrin E.L. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J. Mol. Med. 2008;86:673-678.
23. Amiri F., Paradis P., Reudelhuber T.L., Schiffrin E.L. Vascular Inflammation in Absence of Blood Pressure Elevation in Transgenic Murine Model Overexpressing Endothelin-1 in Endothelial Cells. J. Hypertens. 2008;26:1102-1109.
22. Rivard K., Paradis P., Nemer M., Fiset C. Cardiac-specific overexpression of the human type 1 angiotensin II receptor causes delayed repolarization. Cardiovasc. Res. 2008;78:53-62.
21. Majalahti T., Suo-Palosaari M., Sármán M., Hautala M., Pikkarainen S., Tokola H., Vuolteenaho O., Wang J., Paradis P., Nemer N., Ruskoaho H. Cardiac BNP gene activation by angiotensin II in vivo. Mol. Cell. Endocrinol. 2007;273:59-67.
20. Debrus S., Rahbani L., Marttila M., Delorme B., Paradis P., Nemer, M. The zinc finger-only protein Zfp260 is a novel cardiac regulator and a nuclear effector of 1-adrenergic signaling. Mol. Cell. Biol., 2005;25:8669-8682
19. Wang J., Paradis P., Aries A., Komati H., Lefebvre C., Wang H., Nemer M. Convergence of PKC and JAK-STAT signaling on transcription factor GATA-4. Mol. Cell. Biol., 2005;25:9829-9844
18. Diep Q.N., Amiri F., Benkirane K., Paradis P., Schiffrin E.L. Long-term effects of PPARγ activator pioglitazone on cardiac inflammation in SHRSP. Can. J. Physiol. Pharm. 2004;82:976-85.
17. Aries A., Paradis P., Lefebvre C., Schwartz R.J., Nemer M. (2004) Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2004;101(18):6975-80.
16. Iglarz M., Touyz R.M., Viel E.C., Paradis P., Amiri F., Diep Q.N., Schiffrin E.L. Peroxisome Proliferator-Activated Receptor- and Receptor- Activators Prevent Cardiac Fibrosis in Mineralocorticoid-Dependent. Hypertension. 2003;42:737-743.
15. Marttila M., Hauala N., Paradis P., Toth M., Vuolteennaho O., Nemer M., Ruskoaho H. GATA factors mediate transcriptional activation of the B-type natriuretic peptide gene expression in response to hemodynamic stress. Endocrinology. 2001;142(11):4693-4700.
14. van Katz J.P., Methot D, Paradis P., Silversides D.W., Reudelhuber T.L. Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice: direct and indirect effects of angiotensin II on the heart. J Biol Chem. 2001;276:44012-44017.
13. Morin S., Paradis P., Aries A., Wilkes B.C., Nemer M. SRF/GATA ternary complex required for nuclear signaling by a G protein coupled receptor. Mol. Cell. Biol. 2001;21:1036-1044. 1These authors contributed equally to this work.
12. Paradis P., Dali-Youcef N., Paradis F.W., Thibault G., Nemer M. Overexpression of angiotensin II type 1 receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc. Natl. Acad. Sci. USA. 2000;97:931-936.
11. Charron F., Paradis P., Nemer M. Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression. Mol. Cell. Biol. 1998;19:4355-4365
10. Mazur W., Ali M.N., Khan M.M., Dabaghi S.F., DeFelice C.A., Paradis P., Butler E.B., Wright A.E., Fajardo L.F., French B.A., Raizner A.E. (1996) High dose rate intracoronary radiation for inhibition of neointimal formation in the stented and balloon-injured porcine models of restenosis: angiographic, morphometric and histopathologic analysis. Int J. Radiat. Oncol. Biol. Phys. 1996;36:777-788.
9. Paradis P., MacLellan W.R., Belaguli N.S., Schwartz R.J. and Schneider, M.D. Serum response factor mediates AP-1-dependent induction of the skeletal -actin promoter in ventricular myocytes. J. Biol. Chem. 1996;271:10827-10833.
8. Marchetti B., Morale M.C., Paradis P., Bouvier M. Characterization, expression, and hormonal control of a thymic beta 2-adrenergic receptor. Am J Physiol. 1994;267:E718-31
7. Bélichard P., Savard P., Cardinal R., Nadeau R., Gosselin H., Paradis P., Rouleau J.L. Markedly different effects on ventricular remodeling result in a decrease in inducibility of ventricular arrhythmias. J. Am. Coll. Cardiol. 1994;23:505-513.
6. Paradis P., Dumont M., Bélichard P., Rouleau J.L., Lemaire S., Brakier-Gingras L. Increased preproenkephalin A gene expression in rat heart after induction of a myocardial infarction. Biochem. Cell. Biol. 1992;70:593-598.
5. Paradis P., Lambert C., Rouleau J.L. Antagonism of the myocardial effects of T3 by amiodarone: an additional mechanism for its in vivo hypothyroid-like effects. Can. J. Phys. Pharm. 1991;69:865-870.
4. Shenasa H., Rouleau J.L., Vermeulen M., Paradis P., Stephens H., Cardinal M., de Champlain J. Chronic doxorubicin cardiomyopathy in rabbits: cumulative dose-dependency and unique characteristic of its failing myocardium. Cardiovasc. Res. 1990;24:591-604, 1990.
3. Paradis P., Rouleau J.L., Shenasa H., Brakier-Gingras L. Protein synthesis is increased in heart failure induced by low dose adriamycin in rabbits. Can. J. Phys. Pharm. 1989;67:197-207.
2. Lambert C., Cardinal R., Vermeulen M., Lamontagne D., Nadeau R., Paradis P., Rouleau J.L. Lack of relation between the ventricular refractory period prolongation by amiodarone and the thyroid state in rats. J. Pharm. Exp. Ther. 1987;242:320-325.
1. Rouleau J.L., Paradis P., Shenasa H., Juneau C. Faster time to peak tension and velocity of shortening in right versus left ventricular trabeculae and papillary muscles of dogs. Circ. Res. 1986;59:556-561.

Book Chapters
4. Rautureau Y., Paradis P., Schiffrin E.L. Generation of a mouse model with inducible and smooth muscle cell specific loss of the expression of peroxisome proliferator-activated receptor . In: Touyz RM, Schiffrin EL, eds. Hypertension: Methods and Protocols. New York, NY: Springer New York; 2017:381-407.
3. Barhoumi T., Paradis P., Mann K.K., Schiffrin E.L. Isolation of immune cells for adoptive transfer. In: Touyz RM, Schiffrin EL, eds. Hypertension: Methods and Protocols. New York, NY: Springer New York; 2017:321-344.
2. Paradis P. and Schiffrin E.L. Renin-Angiotensin-Aldosterone System and Pathobiology of Hypertension. In: DeMello WC, Frohlich ED, editors. Renin Angiotensin System and Cardiovascular Disease. 2009:35-57.
1. Nemer M., Dali-Youcef N., Wang H., Aries A. and Paradis P. Mechanisms of angiotensin II-dependent progression to heart failure. (2006) Heart failure: molecules, mechanisms and therapeutic targets. John Wiley & Sons Ltd, Chichester UK (Novartis Foundation Symposium 274) p 58-72.
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.